Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching.

Yonsei Med J · 2017 · PMC5290007 · PMID 28120558

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

significantly not differentno p-value reported

Conclusion In this cohort of patients treated with BES or ZES, the rate of MACCEs at 1 year was low and significantly not different between both groups.

also in 90 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.